Appointing a Legal Representative for Clinical Trials in Turkey
Multinational clinical trials offer foreign pharmaceutical companies the opportunity to bring innovative treatments to a broader patient population. However, expanding the research footprint also brings the complex requirement of complying with diverse international regulations. For pharmaceutical companies and Contract Research Organizations (CROs), one of the most critical legal steps in cross-border operations is the obligation to appoint a local legal representative.
As a pharmaceutical law firm in Turkey, we frequently advise global sponsors through the details of the Turkish Pharmaceutical and Medical Device Agency (TITCK) clinical trial guidelines. In this guide, we break down the legal requirements for foreign sponsors in Turkey and compare them with the practices in the European Union (EU) and the United States (US).
The Legal Framework: Clinical Trial Legal Representative in Turkey
Under the Regulation on Clinical Trials of Human Medicinal Products in force in Turkey, clear legal boundaries stipulate how cross-border trials must be managed. In cases where the sponsor is not established in Turkey, the relevant sponsor ensures that a real or legal person established in Turkey acts as its legal representative.
This appointment is not merely a communicative formality; it is an active legal duty that binds the foreign sponsor to the Turkish Ministry of Health and conducts serious joint and several liability implications. The core responsibilities include:
- Full Compliance and Responsibility: This legal representative is responsible for ensuring compliance with the sponsor’s obligations under Clinical Trial laws and regulations and is the addressee of all communications required to be made with the sponsor under the Regulation.
- Official Communication: Any communication with this legal representative is considered as communication with the sponsor.
- Financial Liability: All financial liabilities of the trials within the scope of this Regulation belong to the sponsor and, if present, its legal representative and other delegated parties.
- Application Authority: For sponsors not established in Turkey, the legal representative or the CRO established in Turkey to which tasks have been delegated, is authorized and responsible for making all applications and notifications to the Agency and the ethics committee.
Global Perspective: US Agent vs. Turkish Legal Representative & EU CTR
One of the biggest hurdles for foreign sponsor clinical trials in Turkey is understanding how local rules map onto familiar Western frameworks. Interestingly, the Turkish regulation was prepared within the framework of harmonization with the European Union legislation, explicitly taking into account the Clinical Trials Regulation (EU) No 536/2014.
European Union (CTR 536/2014): The EU’s Clinical Trials Regulation (CTR) requires sponsors not established within the EU to appoint a Legal Representative within the Union. Because Turkish legislation was harmonized with the EU CTR, the communication and compliance responsibilities of the legal representative in Turkey show direct parallelism with EU expectations, making compliance relatively streamlined for European sponsors.
United States (FDA – 21 CFR Part 312): For Investigational New Drug (IND) applications managed by the FDA, foreign sponsors must countersign their applications via a “US Agent” or an authorized attorney residing in the US. While the US Agent serves as an administrative contact point, the regulation in Turkey imposes a much stricter joint and several liability on the legal representative and the CRO. In Turkey, your local representative is financially and legally on the hook alongside the sponsor.
CRO Contracts Turkey: Structuring Your Legal Agreements
To manage the operational burden of conducting research abroad, the sponsor may delegate any or all of its tasks to a person, company, institution, or organization through a written contract. However, this delegation does not eliminate the sponsor’s responsibility, especially regarding the safety of the subjects and the reliability and quality of the data.
When drafting your CRO contracts in Turkey, our law firm recommends focusing on two critical areas:
- Drawing Liability Limits: The sponsor and the delegated party are jointly responsible for the results of the work and transactions subject to the contract. Because financial responsibility extends to the legal representative, internal recourse conditions must be precisely defined. Your contracts must clearly allocate risk, indemnify the appropriate parties, and be supported by robust local clinical trial insurance policies.
- Balancing Trade Secrets and Transparency: The written contract made between the sponsor and its legal representative is submitted to the ethics committee and the Agency as part of the trial applications. It is vital that these agreements are drafted with legal precision—providing enough operational detail to satisfy the TITCK, without unnecessarily exposing your company’s core trade secrets.
Legal Disclaimer: The information provided in this article is for general informational purposes only and does not constitute legal advice, professional counsel, or a binding legal opinion. While we strive to ensure the accuracy of the content based on the this article, laws and regulations are subject to change and interpretation. Accessing this article does not establish an attorney-client relationship between the reader and Karacabey Legal. We recommend consulting with a qualified attorney regarding your specific legal situation or compliance obligations before taking any action based on this content.
